CI 0694
Alternative Names: Antigen Specific Immunomodulator; ASIM; SulfasimLatest Information Update: 02 Jul 2002
At a glance
- Originator Cortech
- Class
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Drug hypersensitivity
Most Recent Events
- 29 Feb 2000 Discontinued - Phase-I for Drug hypersensitivity in USA (unspecified route)
- 27 Jul 1999 No-Development-Reported for Drug hypersensitivity in USA (Unknown route)
- 27 May 1997 New profile